{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T01:17:14Z","timestamp":1783387034208,"version":"3.54.6"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["16K07143"],"award-info":[{"award-number":["16K07143"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["16K07161"],"award-info":[{"award-number":["16K07161"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["17K10620"],"award-info":[{"award-number":["17K10620"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["17K10621"],"award-info":[{"award-number":["17K10621"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["17K10623"],"award-info":[{"award-number":["17K10623"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["18K07194"],"award-info":[{"award-number":["18K07194"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["18cm0106502h0003"],"award-info":[{"award-number":["18cm0106502h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00280-018-3714-5","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T13:59:41Z","timestamp":1541080781000},"page":"145-150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial"],"prefix":"10.1007","volume":"83","author":[{"given":"Koji","family":"Murono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Ishimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenobu","family":"Emoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Hiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Otani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Shuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Nozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,1]]},"reference":[{"key":"3714_CR1","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1046\/j.1365-2168.2002.02274.x","volume":"89","author":"DG Jayne","year":"2002","unstructured":"Jayne DG, Fook S, Loi C, Seow-Choen F (2002) Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89:1545\u20131550","journal-title":"Br J Surg"},{"key":"3714_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-017-1101-6","volume":"23","author":"T Watanabe","year":"2018","unstructured":"Watanabe T, Muro K, Ajioka Y et al (2018) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol 23:1\u201334","journal-title":"Int J Clin Oncol"},{"key":"3714_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1200\/JCO.2011.37.1039","volume":"30","author":"J Franko","year":"2012","unstructured":"Franko J, Shi Q, Goldman CD et al (2012) Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 30:263\u2013267","journal-title":"J Clin Oncol"},{"key":"3714_CR4","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP et al (2016) Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol 17:1709\u20131719","journal-title":"Lancet Oncol"},{"key":"3714_CR5","first-page":"15","volume":"38","author":"K Murono","year":"2018","unstructured":"Murono K, Kawai K, Hata K et al (2018) Regimens of intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer. Anticancer Res 38:15\u201322","journal-title":"Anticancer Res"},{"key":"3714_CR6","doi-asserted-by":"crossref","first-page":"55657","DOI":"10.18632\/oncotarget.17497","volume":"8","author":"CQ Huang","year":"2017","unstructured":"Huang CQ, Min Y, Wang SY et al (2017) Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence. Oncotarget 8:55657\u201355683","journal-title":"Oncotarget"},{"key":"3714_CR7","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal VJ, van Ruth S, de Bree E et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737\u20133743","journal-title":"J Clin Oncol"},{"key":"3714_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","volume":"28","author":"D Elias","year":"2010","unstructured":"Elias D, Gilly F, Boutitie F et al (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28:63\u201368","journal-title":"J Clin Oncol"},{"key":"3714_CR9","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/SLA.0b013e3182263933","volume":"254","author":"F Quenet","year":"2011","unstructured":"Quenet F, Goere D, Mehta SS et al (2011) Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg 254:294\u2013301","journal-title":"Ann Surg"},{"key":"3714_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejca.2015.09.017","volume":"53","author":"PH Cashin","year":"2016","unstructured":"Cashin PH, Mahteme H, Spang N et al (2016) Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer 53:155\u2013162","journal-title":"Eur J Cancer"},{"key":"3714_CR11","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.1992.10.9.1485","volume":"10","author":"M Markman","year":"1992","unstructured":"Markman M, Rowinsky E, Hakes T et al (1992) Phase I trial of intraperitoneal taxol: a gynecologic oncology group study. J Clin Oncol 10:1485\u20131491","journal-title":"J Clin Oncol"},{"key":"3714_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000209277","volume":"76","author":"H Ishigami","year":"2009","unstructured":"Ishigami H, Kitayama J, Otani K et al (2009) Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology 76:311\u2013314","journal-title":"Oncology"},{"key":"3714_CR13","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1002\/cncr.28204","volume":"119","author":"H Yamaguchi","year":"2013","unstructured":"Yamaguchi H, Kitayama J, Ishigami H, Emoto S, Yamashita H, Watanabe T (2013) A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer 119:3354\u20133358","journal-title":"Cancer"},{"key":"3714_CR14","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s10637-016-0369-0","volume":"34","author":"N Takahara","year":"2016","unstructured":"Takahara N, Isayama H, Nakai Y et al (2016) Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. Investig New Drugs 34:636\u2013642","journal-title":"Investig New Drugs"},{"key":"3714_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/SLA.0000000000001705","volume":"265","author":"S Satoi","year":"2017","unstructured":"Satoi S, Fujii T, Yanagimoto H et al (2017) Multicenter phase II study of intravenous and intraperitoneal paclitaxel with S-1 for pancreatic ductal adenocarcinoma patients with peritoneal metastasis. Ann Surg 265:397\u2013401","journal-title":"Ann Surg"},{"issue":"19","key":"3714_CR16","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami H, Fujiwara Y, Fukushima R et al (2018) Phase III Trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC Trial. J Clin Oncol 36(19):1922\u20131929","journal-title":"J Clin Oncol"},{"key":"3714_CR17","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1159\/000110005","volume":"53","author":"A Hribaschek","year":"2007","unstructured":"Hribaschek A, Meyer F, Schneider-Stock R, Pross M, Ridwelski K, Lippert H (2007) Comparison of intraperitoneal with intravenous administration of taxol in experimental peritoneal carcinomatosis. Chemotherapy 53:410\u2013417","journal-title":"Chemotherapy"},{"key":"3714_CR18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359\u2013374","journal-title":"Cancer Treat Res"},{"key":"3714_CR19","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013\u20132019","journal-title":"J Clin Oncol"},{"key":"3714_CR20","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/jjco\/hyq069","volume":"40","author":"T Doi","year":"2010","unstructured":"Doi T, Boku N, Kato K et al (2010) Phase I\/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 40:913\u2013920","journal-title":"Jpn J Clin Oncol"},{"key":"3714_CR21","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andre","year":"2004","unstructured":"Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343\u20132351","journal-title":"N Engl J Med"},{"key":"3714_CR22","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","volume":"25","author":"BJ Giantonio","year":"2007","unstructured":"Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539\u20131544","journal-title":"J Clin Oncol"},{"key":"3714_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/bjc.2011.201","volume":"105","author":"J Cassidy","year":"2011","unstructured":"Cassidy J, Clarke S, Diaz-Rubio E et al (2011) XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 105:58\u201364","journal-title":"Br J Cancer"},{"key":"3714_CR24","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S1470-2045(12)70509-0","volume":"13","author":"A de Gramont","year":"2012","unstructured":"de Gramont A, Van Cutsem E, Schmoll HJ et al (2012) Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 13:1225\u20131233","journal-title":"Lancet Oncol"},{"key":"3714_CR25","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S1470-2045(13)70490-X","volume":"14","author":"Y Yamada","year":"2013","unstructured":"Yamada Y, Takahari D, Matsumoto H et al (2013) Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14:1278\u20131286","journal-title":"Lancet Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3714-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3714-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3714-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T11:35:05Z","timestamp":1589628905000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3714-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["3714"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3714-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,1]]},"assertion":[{"value":"18 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"K. Muro is on the advisory board meeting for Bristol-Myers Squibb and Nippon Kayaku Co, Ltd. All remaining authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee of the University of Tokyo (P2015038-11X) and with the 1964 Helsinki declaration and its later amendments. The study was registered in the University Hospital Medical Information Network Clinical Trial Registry (UMIN-CTR) (UNIN000022924).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}